Inflammatory Bowel Disease: World Market 2010-2025

Report Overview

Table of Contents

1499

Select License Type

£1,499.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,999.00	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,999.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,499.00	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	23 March 2010
Number of Pages	125
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Visiongain
File Format	PDF

Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous year. We predict that the overall market for IBD drugs will expand from 2010 onwards. Main commercial drivers will be disease prevalence, improving diagnosis and wider access to treatments. Currently, IBD is under-diagnosed, especially in developing countries. As governments and other healthcare providers address chronic illnesses like IBD, this market will expand in many countries.

Inflammatory Bowel Disease: World Market 2010-2025 analyses commercial prospects for drugs used to treat IBD, including R&D pipeline developments. How much impact will monoclonal antibodies have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will the European IBD market share compare with the Asian market share in 2015, 2020 and 2025? Our report covers questions such as these, providing answers to benefit your work.

In particular, this report covers market prospects for the following agents:
• Aminosalicylates/5-ASA
• Corticosteroids
• Immunomodulators
• Antibiotics
• Monoclonal antibodies/biologics.

The IBD treatment market is complex. Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our new study reveals.

Comprehensive analysis of the global IBD drug market

Inflammatory Bowel Disease: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 65 tables and figures included, as well as four original interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Inflammatory Bowel Disease: World Market 2010-2025

This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of prospects for inflammatory bowel disease treatments from 2010 to 2025, including predicted revenues, growth rates and other data for leading products
• You will receive an overall forecast for the global IBD market from 2010 to 2025, as well as those for main classes, with comprehensive discussions and other supporting information
• You will receive geographical sales forecasts for that sector
• You will find out where the IBD market is heading - both technologically and commercially - from 2010 onwards
• You will discover the prospects for leading companies from 2010 onwards
• You will identify R&D pipeline developments and up-and-coming products
• You will analyse the drivers, restraints, competition and opportunities influencing the IBD sector
• You will investigate under-met needs, with therapeutic requirements and commercial opportunities discussed
• You will discover expert views from our survey, including full interview transcripts.

You can obtain this report today

Nobody with an interest in the IBD pharmaceutical sector should overlook this new study. We predict that total revenues will increase for products treating those recalcitrant disorders. With rising demand worldwide and unmet needs, this market holds significant potential for technological development and revenue growth. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£1,499.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,999.00	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,999.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,499.00	Add to Wishlist
Change Currency	GBP EURO USD

Table of Contents
1. Executive Summary
1.1 Inflammatory Bowel Disease Market Review
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. What Is Inflammatory Bowel Disease?
2.1 Definition
2.2 Types of IBD
2.3 Signs, Symptoms and Associated Conditions
2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations and Other Events
2.3.2 Pyoderma Gangrenosum
2.3.3 Primary Sclerosing Cholangitis
2.4 Ulcerative Colitis
2.5 Crohn's Disease
2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
2.7 What Causes Inflammatory Bowel Disease?
2.7.1 Genetic Factors
2.7.2 Environmental Factors
2.8 How Common is Inflammatory Bowel Disease?
2.8.1 Geographical Variation in Rates of IBD
2.9 Socioeconomic Costs of IBD
2.9.1 The Individual Cost of IBD

3. Treating Inflammatory Bowel Disease
3.1 Treatment Goals
3.2 Drug Classes Used in IBD Treatment
3.2.1 Aminosalicylates
3.2.2 Corticosteroids
3.2.3 Immunomodulators
3.2.4 Monoclonal Antibodies
3.3 Surgery
3.3.1 Surgery for Ulcerative Colitis
3.3.2 Surgery for Crohn's Disease
3.4 Alternative Treatments
3.4.1 Faecal Bacteriotherapy and Pre/Probiotics
3.4.2 Helminthic Therapy
3.4.3 Complementary Medicine
3.5 Treatment Protocol
3.5.1 Recent Trial Data

4. The World Inflammatory Bowel Disease Market, 2010-2025
4.1 Non-Biologic Drugs
4.1.1 IBD-Specific Drugs (Intestinal Anti-inflammatories)
4.1.2 Drugs not Specific to IBD (Others)
4.2 Biologic Drugs
4.3 Total Market
4.4 Market Shares by Disease Type
4.5 Market Forecast: Inflammatory Bowel Disease Sales
4.6 Market Forecasts: Sales by Disease Type
4.7 Market Forecasts: Sales by Therapy Type

5. Leading Drugs for Inflammatory Bowel Disease, 2010-2025
5.1 Intestinal Anti-inflammatory Drugs
5.2 Asacol
5.2.1 Asacol: Background
5.2.2 Asacol: Sales Forecast and Analysis
5.3 Pentasa
5.3.1 Pentasa: Background
5.3.2 Pentasa: Sales Forecast and Analysis
5.4 Entocort
5.4.1 Entocort: Background
5.4.2 Entocort: Sales Forecast and Analysis
5.5 Lialda
5.5.1 Lialda: Background
5.5.2 Lialda: Sales Forecast and Analysis
5.6 Salofalk
5.6.1 Salofalk: Background
5.6.2 Salofalk: Sales Forecast and Analysis
5.7 Comparison of Intestinal Anti-inflammatory Sales Forecasts
5.8 Biologics
5.9 Remicade
5.9.1 Remicade: Background
5.9.2 Remicade: Sales Forecast and Analysis
5.10 Humira
5.10.1 Humira: Background
5.10.2 Humira: Sales Forecast and Analysis
5.11 Cimzia
5.11.1 Cimzia: Background
5.11.2 Cimzia: Sales Forecast and Analysis
5.12 Tysabri
5.12.1 Tysabri: Background
5.12.2 Tysabri: Sales Forecast and Analysis
5.13 Comparison of Biologic Sales Forecasts

6. The R&D Pipeline for Inflammatory Bowel Disease
6.1 Monoclonal Antibodies
6.1.1 HuZAF
6.1.2 Stelara
6.1.3 Vedolizumab
6.1.4 Simponi
6.2 Small Molecules
6.2.1 Tetomilast
6.2.2 Firategrast
6.3 Antibiotics
6.3.1 Rifaximin
6.3.2 Myoconda
6.4 Nicotine and Buproprion
6.5 Alicaforsen
6.6 Alequel
6.7 MAP Vaccine
6.8 Autologous Stem Cell Transplantation for Crohn's Disease
6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract

7. Leading Companies in the Inflammatory Bowel Disease Sector
7.1 The Largest Companies by Revenue in the Intestinal Anti-inflammatory Market
7.2 Procter & Gamble
7.3 Shire Pharmaceuticals Group
7.4 Prometheus Laboratories
7.5 Ferring Pharmaceuticals
7.6 Kyorin Pharmaceutical

8. Geographical Breakdown of the World IBD Market, 2010-2025
8.1 Intestinal Anti-inflammatory Market: Seven Major Economies
8.2 Intestinal Anti-inflammatory Market: BRICT Countries
8.3 The Global IBD Market: Sales Forecasts by Geographical Area
8.3.1 North America: Sales Forecast, 2010-2025
8.3.2 Europe: Sales Forecast, 2010-2025
8.3.3 Africa, Asia and Australasia: Sales Forecast, 2010-2025
8.3.4 Latin America: Sales Forecast, 2010-2025
8.4 Comparison of Regional Markets: Sales Forecasts, 2010-2025

9. Inflammatory Bowel Disease Market: Opportunities and Challenges Ahead
9.1 SWOT Analysis of the World IBD Market
9.2 Market Drivers
9.2.1 Increasing Disease Incidence
9.2.2 Better Diagnosis
9.2.3 Nature of the Disease
9.2.4 Delivery Systems
9.2.5 Biologics
9.3 Market Restraints
9.3.1 Lack of Understanding of Disease Aetiology
9.3.2 Compliance
9.3.3 Limits of Biologics
9.3.4 A Cure or Vaccine?

10. Interviews with Experts
10.1 Marco Greco
10.1.1 Public Awareness of IBD
10.1.2 The Differences Between European Countries
10.1.3 Drug Companies' Involvement in Awareness Campaigns
10.1.4 Unmet Medical Needs
10.2 Dr Alan Fraser
10.2.1 Autoimmunity vs. Infection Theories
10.2.2 Monoclonal Antibodies
10.2.3 Genotyping
10.2.4 Remaining Therapeutic Gaps
10.2.5 Future Treatments
10.3 Professor Thomas Borody
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP
10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 Potential and Future of Myoconda
10.4 Professor John Hermon-Taylor
10.4.1 Significance of MAP in Crohn's
10.4.2 The Rising Incidence of IBD
10.4.3 Defining IBD
10.4.4 Timeframe of MAP Vaccine
10.4.5 Antibiotic Activity of Other Crohn's Treatments
10.4.6 Alternative Treatments
10.4.7 Ethics of Crohn's Drug Development
10.4.8 Impact of a Vaccine on the Market
10.4.9 On Claims that MAP is Not Implicated in CD

11. Conclusions of the Study
11.1 IBD Sales to 2025 - How High Will The Market Reach?
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatment
11.5 Future IBD Treatments: R&D Efforts Promising
11.6 The IBD Sector: Looking to the Future Confidently

List of Tables
Table 2.1 World Incidence Rates for IBD, 2010
Table 2.2 Prevalence of IBD in Selected Countries, 2010
Table 2.3 Common Misdiagnoses for IBD
Table 3.1 Ancillary Drug Types Used in Inflammatory Bowel Disease, 2010
Table 3.2 Composition of Various 5-ASA Drugs
Table 4.1 Inflammatory Bowel Disease Market: World Sales and Market Shares by Drug Class, 2009
Table 4.2 Studies Comparing the Direct Medical Costs of Crohn's Disease and Ulcerative Colitis
Table 4.3 World IBD Market: Sales by Disease Type, 2009
Table 4.4 World IBD Market: Sales Forecast, 2010-2025
Table 4.5 World IBD Market: Sales Forecast by Disease Type, 2010-2025
Table 4.6 World IBD Market: Sales Forecast by Therapy Type, 2010-2025
Table 5.1 Top-Five Intestinal Anti-Inflammatory Drugs: World Sales, 2009
Table 5.2 Asacol: World Sales Forecast, 2010-2025
Table 5.3 Pentasa: World Sales Forecast, 2010-2025
Table 5.4 Entocort: World Sales Forecast, 2010-2025
Table 5.5 Lialda: World Sales Forecast, 2010-2025
Table 5.6 Salofalk: World Sales Forecast, 2010-2025
Table 5.7 World Sales Forecasts for Leading Intestinal Anti-Inflammatories, 2010-2025
Table 5.8 Biologics for IBD: World Sales, 2009
Table 5.9 Remicade: World Sales Forecast, 2010-2025
Table 5.10 Contraindications for TNF-a Blockers
Table 5.11 Humira: World Sales Forecast, 2010-2025
Table 5.12 Cimzia: World Sales Forecast, 2010-2025
Table 5.13 Tysabri: World Sales Forecast, 2010-2025
Table 5.14 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Table 6.1 Key Pipeline Products for Inflammatory Bowel Disease, 2010
Table 7.1 Intestinal Anti-Inflammatories (IAIs): Largest Companies by Revenue, 2009
Table 7.2 Procter & Gamble: Major IAI Products, 2009
Table 7.3 Shire: Major IAI Products, 2009
Table 7.4 Prometheus: Major IAI Products, 2009
Table 7.5 Prometheus: Diagnostic Tests, 2009
Table 7.6 Ferring: Major IAI Products, 2009
Table 7.7 Kyorin: Major IAI Products, 2009
Table 8.1 IBD Markets of Seven Major Economies: Sales and Market Shares, 2009
Table 8.2 IBD Sales and Market Shares for the Major Emerging Markets (BRICT), 2009
Table 8.3 North America: IBD Sales Forecast, 2010-2025
Table 8.4 Europe: IBD Sales Forecast, 2010-2025
Table 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Table 8.6 Latin America: IBD Sales Forecast, 2010-2025
Table 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025
Table 9.1 SWOT Analysis of the Global IBD Market, 2010

List of Figures
Figure 2.1 Prevalence of IBD in Selected Countries, 2010
Figure 3.1 Treatment Protocols for Inflammatory Bowel Disease, 2010
Figure 4.1 World IBD Market: Sales Shares by Drug Class, 2009
Figure 4.2 World IBD Market: Sales Shares by Disease Type, 2009
Figure 4.3 World IBD Market: Sales Forecast, 2010-2025
Figure 4.4 World IBD Market: Sales Forecasts by Disease Type, 2010-2025
Figure 4.5 World IBD Market: Sales Forecasts by Therapy Type, 2010-2025
Figure 5.1 Top-Five Intestinal Anti-Inflammatories: World Market Shares, 2009
Figure 5.2 Asacol: World Sales Forecast, 2010-2025
Figure 5.3 Pentasa: World Sales Forecast, 2010-2025
Figure 5.4 Entocort: World Sales Forecast, 2010-2025
Figure 5.5 Lialda: World Sales Forecast, 2010-2025
Figure 5.6 Salofalk: World Sales Forecast, 2010-2025
Figure 5.7 World Sales Forecasts for Leading Intestinal Anti-inflammatory Drugs, 2010-2025
Figure 5.8 Biologics for IBD: World Sales, 2009
Figure 5.9 Remicade: World Sales Forecast, 2010-2025
Figure 5.10 Humira: World Sales Forecast, 2010-2025
Figure 5.11 Cimzia: World Sales Forecast, 2010-2025
Figure 5.12 Tysabri: World Sales Forecast, 2010-2025
Figure 5.13 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Figure 7.1 Intestinal Anti-Inflammatories: Largest Companies by Sales, 2009
Figure 8.1 IBD Markets of Seven Major Economies: Sales, 2009
Figure 8.2 IBD Markets of Major Emerging Markets (BRICT): Sales, 2009
Figure 8.3 North America: IBD Sales Forecast, 2010-2025
Figure 8.4 Europe: IBD Sales Forecast, 2010-2025
Figure 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Figure 8.6 Latin America: IBD Sales Forecast, 2010-2025
Figure 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025

Companies Listed
Abbott Laboratories
Amalyte
ARCA
AstraZeneca
Biogen Idec
Cambridge Antibody Technology
Celltech Pharmaceuticals
Centocor Ortho Biotech
ChemoCentryx
China Medical
Cosmo Pharmaceuticals
Crohn's and Colitis Foundation of America
Crohn's and Colitis Foundation of Canada
Dr. Falk Pharma
Elan Corporation
Enzo Biochem
European Federation of Crohn's and Ulcerative Colitis Associations
European Medicines Agency (EMEA)
Evonik Industries
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Giaconda
Giuliani
GlaxoSmithKline
Interneuron
Isis Pharmaceuticals
Johnson & Johnson
King's College, London, UK
Kyorin Pharmaceutical Co.
Medarex
Merck and Co.
Miltenyi Biotec
Nycomed
Otsuka Pharmaceutical Group
PDL BioPharma
Pfizer
Probiotic Therapy Research Centre, Sydney, Australia
Procter & Gamble
Prometheus Laboratories
Protein Design Labs
Royalty Pharma
Salix Pharmaceuticals
sanofi-aventis
Schering-Plough
Shire Pharmaceuticals Group
Takeda Pharmaceutical Company
Tillots Pharma
UCB
University of Auckland, New Zealand

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Inflammatory Bowel Disease: World Market 2010-2025

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Inflammatory Bowel Disease: World Market 2010-2025

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel